HIGHLIGHTS
- What: The second aim of this study was to determine whether this testing approach increased testing costs in Switzerland compared to a model in which all patients newly diagnosed with ovarian cancer are provided with a functional homologous recombination deficiency test (myChoice CDx and Geneva), followed by genetic counselling for those with positive tests. Unlike a Dutch study that proposed a reciprocal testing strategy that combined somatic BRCA testing with somatic next-generation sequencing but did not address homologous recombination deficiency , the Bernese testing approach aims to identify patients with gBRCAmt and homologous recombination deficient ovarian tumours . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.